LPC-DHA Formulations for Brain Uptake via Mfsd2a Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dietary supplements of omega-3 fatty acids, such as DHA, do not effectively increase brain levels due to hydrolysis and require alternative forms like lysophosphatidylcholine (LPC) for efficient uptake, and there is a need for rapid and sustained increase in LPC-DHA levels for neurological conditions like traumatic brain injury.
Innovation Solution
Pharmaceutical compositions comprising phosphatidylcholine-derived compounds carrying omega-3 fatty acids, such as LPC-DHA and LPC-EPA, for intravascular administration to rapidly and sustainably increase brain uptake through intravenous injection or infusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If dietary DHA supplements are administered, then peripheral tissues are enriched with DHA, but brain DHA levels are not appreciably increased
Solution Approach 1:
The patent changes the chemical form of DHA from free DHA or triacylglycerol form to lysophosphatidylcholine (LPC-DHA) form. This parameter change in molecular structure enables direct recognition and uptake by the brain through specific transporters (Mfsd2a) at the blood-brain barrier, resolving the contradiction between peripheral enrichment and brain-specific DHA levels.
Solution Approach 2:
The patent introduces LPC-DHA as an intermediary compound that serves as a bridge between peripheral DHA supplementation and brain DHA uptake. The LPC-DHA form acts as a recognized substrate for brain transporters, facilitating efficient transfer across the blood-brain barrier while maintaining peripheral DHA levels.
2Productivity
If free DHA is administered, then it is absorbed as triacylglycerol in chylomicrons, but it requires extensive metabolic transformations in the liver to form LPC-DHA
Solution Approach 1:
The patent performs the preliminary action of forming LPC-DHA in the diet or supplement before administration. By pre-converting DHA to the LPC form in the manufacturing process, the patent eliminates the need for extensive liver metabolic transformations after administration, significantly reducing the time required for brain DHA enrichment.
3Quantity of substance
If LPC-DHA is administered to increase brain DHA levels, then brain DHA content is more than doubled, but high LPC levels may disrupt cell membranes
Solution Approach 1:
The patent carefully controls the concentration and formulation parameters of LPC-DHA to achieve high brain DHA levels while maintaining safety. By optimizing the dose and using controlled release formulations, the patent achieves the desired brain enrichment without reaching toxic LPC levels that would disrupt cell membranes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increases omega-3 fatty acid uptake into the brain at a fast rate and for a prolonged period, potentially treating neurological conditions by maintaining high LPC levels in serum without membrane disruption.
Implementation Method 1
The recent demonstration of a transporter (Mfsd2a) at the blood brain barrier (Nature. 2014 May 22; 509(7501):503-6.), which specifically transports LPC-DHA but not free DHA
Implementation Method 2
dietary DHA provided in the sn-1 position of phosphatidylcholine (PC) or in the form of LPC in the diet, may escape the hydrolysis by pancreatic PLA2
Data Source
AI summary
The present invention relates to pharmaceutical formulations of phospholipids, and in particular pharmaceutical formulations which are administered intravascularly such as intravenously. In particular, the present invention provides pharmaceutical compositions for intravascular administration comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy.